Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Jean Baptiste Assié"'
Autor:
Christos Chouaid, Jean Baptiste Assié, Pascal Andujar, Cecile Blein, Charlène Tournier, Alexandre Vainchtock, Arnaud Scherpereel, Isabelle Monnet, Jean Claude Pairon
Publikováno v:
Cancer Medicine, Vol 7, Iss 4, Pp 1102-1109 (2018)
Abstract This study was undertaken to determine the healthcare burden of malignant pleural mesothelioma (MPM) in France and to analyze its associations with socioeconomic deprivation, population density, and management outcomes. A national hospital d
Externí odkaz:
https://doaj.org/article/18eab90d15a3470197deb7c114050996
Autor:
Hélène Goussault, Sébastien Gendarme, Jean‐Baptiste Assié, Camille Jung, Salomé Epaud, Christelle Algans, Noémie Salaun‐Penquer, Mathilde Rousseau, Andrea Lazatti, Christos Chouaïd
Publikováno v:
Cancer Medicine, Vol 11, Iss 24, Pp 5025-5034 (2022)
Abstract Background Despite therapeutic advances, lung cancer remains the first cause of death from cancer. The main objective of this study was to identify risk factors associated with death within 3‐months of the first hospitalization for lung ca
Externí odkaz:
https://doaj.org/article/c0e458041f3949f38b24890f428007eb
Autor:
Clément Meiller, François Montagne, Theo Z. Hirsch, Stefano Caruso, Julien de Wolf, Quentin Bayard, Jean-Baptiste Assié, Léa Meunier, Yuna Blum, Lisa Quetel, Laure Gibault, Ecaterina Pintilie, Cécile Badoual, Sarah Humez, Françoise Galateau-Sallé, Marie-Christine Copin, Eric Letouzé, Arnaud Scherpereel, Jessica Zucman-Rossi, Françoise Le Pimpec-Barthes, Marie-Claude Jaurand, Didier Jean
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-16 (2021)
Abstract Background Malignant pleural mesothelioma (MPM) is a heterogeneous cancer. Better knowledge of molecular and cellular intra-tumor heterogeneity throughout the thoracic cavity is required to develop efficient therapies. This study focuses on
Externí odkaz:
https://doaj.org/article/f28dbb2176c54bca878c197186dd3f4f
Autor:
Thierry Landre, Kader Chouahnia, Gaëtan Des Guetz, Boris Duchemann, Jean-Baptiste Assié, Christos Chouaïd
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Introduction: Platin-based chemotherapy (CT) has long been the first-line standard-of-care for patients with extensive-stage small-cell lung cancer (ES–SCLC). Adding immune-checkpoint inhibitor(s) to CT (ICI+CT) in this setting is an option of inte
Externí odkaz:
https://doaj.org/article/98a3806216fe4bb49fd3d4807ffea523
Autor:
Jean-Baptiste Assié, Romain Corre, Matteo Giaj Levra, Christophe Yannick Calvet, Anne-Françoise Gaudin, Valentine Grumberg, Baptiste Jouaneton, François-Emery Cotté, Christos Chouaïd
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Objective: To describe long-term outcomes of patients treated with nivolumab for advanced non-small cell lung cancer (aNSCLC) in everyday clinical practice in France, with a focus on patients aged ⩾80 years, patients with renal impairment and patie
Externí odkaz:
https://doaj.org/article/54cab800c9de419a8b9e70d8954776a5
Autor:
Julia Grambow-Velilla, Romain-David Seban, Kader Chouahnia, Jean-Baptiste Assié, Laurence Champion, Nicolas Girard, Gerald Bonardel, Lise Matton, Michael Soussan, Christos Chouaïd, Boris Duchemann
Publikováno v:
Cancers; Volume 15; Issue 8; Pages: 2223
Background: We aimed to evaluate the prognostic value of imaging biomarkers on 18F-FDG PET/CT in extensive-stage small-cell lung cancer (ES-SCLC) patients undergoing first-line chemo-immunotherapy. Methods: In this multicenter and retrospective study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40bd9c897d7a3d80819dc669b9e4f1fb
Autor:
Valentine Grumberg, Christos Chouaïd, François-Emery Cotté, Baptiste Jouaneton, Ronan Jolivel, Anne-Françoise Gaudin, Dorothée Reynaud, Jean-Baptiste Assié, Isabelle Borget
Publikováno v:
Journal of Medical Economics. 25:691-699
In advanced cancers, healthcare resource utilization (HCRU) and costs usually increase until death. However, few studies have measured HCRU over time in patients treated with immunotherapies. The objective was to describe the evolution of HCRU and co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a36139cbb51d5cf300b73fd0e27eea0
https://doi.org/10.1080/13696998.2022.2079291
https://doi.org/10.1080/13696998.2022.2079291
Autor:
Frédéric Schlemmer, Simon Valentin, Laurent Boyer, Anne Guillaumot, François Chabot, Clairelyne Dupin, Pierre Le Guen, Gwenael Lorillon, Anne Bergeron, Damien Basille, Julia Delomez, Claire Andrejak, Valentine Bonnefoy, Hélène Goussault, Jean-Baptiste Assié, Pascaline Choinier, Anne-Marie Ruppert, Jacques Cadranel, Maria Chiara Mennitti, Mehdi Roumila, Charlotte Colin, Sven Günther, Olivier Sanchez, Thomas Gille, Lucile Sésé, Yurdagul Uzunhan, Morgane Faure, Maxime Patout, Capucine Morelot-Panzini, Pierantonio Laveneziana, Maeva Zysman, Elodie Blanchard, Chantal Raherison-Semjen, Violaine Giraud, Etienne Giroux-Leprieur, Stéfanie Habib, Nicolas Roche, Anh Tuan Dinh-Xuan, Islem Sifaoui, Pierre-Yves Brillet, Camille Jung, Emmanuelle Boutin, Richard Layese, Florence Canoui-Poitrine, Bernard Maitre
Publikováno v:
European Respiratory Journal
European Respiratory Journal, 2023, 61 (4), pp.2201532. ⟨10.1183/13993003.01532-2022⟩
European Respiratory Journal, 2023, 61 (4), pp.2201532. ⟨10.1183/13993003.01532-2022⟩
BackgroundSurvivors of severe-to-critical coronavirus disease 2019 (COVID-19) may have functional impairment, radiological sequelae and persistent symptoms requiring prolonged follow-up. This pragmatic study aimed to describe their clinical follow-up
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f573882239dc71213797ce124c5d1571
https://hal-u-picardie.archives-ouvertes.fr/hal-03958196/document
https://hal-u-picardie.archives-ouvertes.fr/hal-03958196/document
Autor:
Christos Chouaid, Jean-Baptiste Assié, Boris Duchemann, Claire Davoine, Gregoire Justeau, Kader Chouahnia, Thierry Landre, Cherifa Taleb
Publikováno v:
Cancer Immunology, Immunotherapy. 71:719-726
The most frequent mutation in advanced non-small–cell lung cancer (NSCLC), Kirsten rat-sarcoma viral oncogene (KRAS) is found in 20–25% of these patients’ tumors. While phase III trials on therapies targeting KRAS, especially KRASG12C, are ongo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89cd25154f7763ccb795f8ce364ad8a0
https://doi.org/10.1007/s00262-021-03031-1
https://doi.org/10.1007/s00262-021-03031-1
Autor:
null Sabine Paternot, null Eric Raspé, null Clément Meiller, null Maxime Tarabichi, null Jean‐Baptiste Assié, null Frederick Libert, null Myriam Remmelink, null Xavier Bisteau, null Patrick Pauwels, null Yuna Blum, null Nolwenn Le Stang, null Séverine Tabone‐Eglinger, null Françoise Galateau‐Sallé, null Christophe Blanquart, null Jan P. Van Meerbeeck, null Thierry Berghmans, null Didier Jean, null Pierre P. Roger
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6932f8a919a7a1350efb1a248ea44da
https://doi.org/10.1002/1878-0261.13351/v2/response1
https://doi.org/10.1002/1878-0261.13351/v2/response1